22nd Century Group, Inc. is a biotechnology company specializing in the development of plant-based products with reduced nicotine content. Leveraging proprietary plant breeding and genetic engineering technologies, the company has created a platform that modulates nicotine levels in tobacco plants, enabling the production of very low-nicotine (VLN®) cigarettes and other reduced-risk products. This unique approach aligns with public health goals to decrease nicotine dependence while offering conventional adult smokers alternative products that more closely resemble traditional cigarettes.
In addition to its core tobacco-focused initiatives, 22nd Century Group has diversified into cannabinoid research through its wholly owned subsidiary, PhytaTech. This division develops cannabinoid-rich industrial hemp varieties and extraction technologies aimed at supporting pharmaceutical, cosmetic and nutraceutical markets. By applying similar plant science techniques to both tobacco and hemp, the company seeks to extend its expertise in crop genetics and processing to a broader range of botanical products.
Founded in 1998 and headquartered in Purchase, New York, 22nd Century Group operates research and production facilities in the United States and Europe. The company’s R&D infrastructure includes advanced greenhouses, pilot processing plants and analytical laboratories. Over the years, it has collaborated with government agencies, public health organizations and academic institutions to advance its low-nicotine tobacco agenda and secure regulatory approvals.
Under the leadership of President and Chief Executive Officer Bill Boor and Chairman Stephen S. Stanford, 22nd Century Group continues to expand its intellectual property portfolio and streamline pathways to market. With strategic partnerships and licensing arrangements in key markets, the company targets regulated adult-use channels in North America, Asia and select European countries. Its long-term objective is to generate sustainable revenue streams through proprietary product offerings and technology licensing, while contributing to global harm-reduction efforts.
AI Generated. May Contain Errors.
Free XXII Stock Alerts